RESOMER RG 503 H Bioresorbable PLGA Drug Delivery Grade is a poly(D,L-lactide-co-glycolide) copolymer with a nominal lactide:glycolide molar ratio of 50:50 and free carboxylic acid terminal functionality. The grade is supplied as a solid polymer and is used as a release-controlling matrix in long-acting injectable and implantable drug delivery systems. Manufacturer release specifications define the product through inherent viscosity in the range 0.32–0.44 dL/g, a glass transition temperature of 44–48 °C, and a molecular weight reported as 24,000–38,000 Da by gel permeation chromatography. The D,L-lactide content renders the matrix amorphous, so no crystalline melting point is observed under standard ISO 11357-2 differential scanning calorimetry; the glass transition is the relevant thermal event for processing. The polymer is soluble in dichloromethane, chloroform, acetone, ethyl acetate, and N-methyl-2-pyrrolidone, but residual water in the solvent should be below 0.1% for high-recovery solution preparation. The acid-terminated structure differentiates the grade from ester-capped PLGA materials with otherwise similar monomer composition. Because the material is bioresorbable, hydrolytic degradation in aqueous media produces lactic acid and glycolic acid, which are removed from the body by normal metabolic pathways. The product requires protection from atmospheric moisture and should be inspected for agglomeration or discoloration before use.

What Distinguishes RESOMER RG 503 H from Ester-Terminated PLGA Grades?

The terminal end-group chemistry of RG 503 H imposes measurable differences in hydrophilicity and initial degradation behavior. Free carboxylic acid groups contribute to an acid number limit of at least 7 mg KOH/g, whereas an ester-capped PLGA of equivalent molecular weight normally exhibits a substantially lower acid number. The higher concentration of terminal carboxyl groups increases water uptake at the polymer–aqueous interface and can reduce the induction period before mass loss in phosphate-buffered saline at 37 °C. In bulk-eroding systems, acid-catalyzed hydrolysis accelerates once water enters the matrix, but the pre-existing acid chain ends in RG 503 H provide additional catalytic sites from the earliest stages of hydration. This property is relevant when rapid release or shorter depot persistence is required. In contrast, an ester-terminated grade of the same 50:50 monomer ratio typically shows delayed water uptake and slower early-stage mass loss under identical static incubation. Comparative dissolution testing should follow USP <711> with flow-through cells or sample-and-separate methods, using phosphate-buffered saline at pH 7.4 and 37 °C. Published kinetic constants for this specific grade under all apparatus conditions are limited; formulation-specific release data are required.

Among the acid-terminated 50:50 PLGA series, the viscosity segment occupied by RG 503 H is intermediate rather than extreme. The lower-molecular-weight grade RG 502 H and the higher-molecular-weight grade RG 504 H bracket its processing behavior. In solvent-based microsphere manufacturing, the polymer is dissolved in a water-immiscible organic phase such as dichloromethane or ethyl acetate, and the resulting organic phase is emulsified into an aqueous continuous phase containing a stabilizer such as polyvinyl alcohol. A production-scale rotor-stator homogenizer or membrane emulsification unit produces the primary oil-in-water emulsion. Solvent extraction and evaporation then harden the droplets into microspheres. With RG 503 H, the free acid end groups increase the affinity of the matrix for water during hardening; this can change the early porosity and may alter the partition of weakly basic drug substances toward the polymer phase. The organic phase viscosity is controlled by the inherent viscosity of the grade, and high-viscosity batches may require adjustment of homogenizer tip speed or solvent ratio to maintain the target mean particle size. Residual solvent removal is performed by vacuum drying or lyophilization, and release limits for dichloromethane and ethyl acetate are established according to ICH Q3C. Because the polymer is hygroscopic, exposure to ambient relative humidity above 60% can increase moisture uptake; drying to residual moisture below 0.1% before melt processing is standard. Hot-melt extrusion of RG 503 H is typically performed at barrel temperatures between 120 °C and 160 °C, but published data for specific screw profiles and L/D ratios with this exact grade are limited; process capability studies are required before scale-up. The polymer should not be combined with strong oxidizing agents, strongly alkaline aqueous media, or primary amine-bearing additives unless compatibility has been demonstrated by forced-degradation testing.

Specification Boundaries and Incoming QC Verification

The following release parameters are used to distinguish RG 503 H from adjacent PLGA grades and to confirm fitness for drug delivery processing. The values are manufacturer release ranges; compendial harmonization is not automatic.

Incoming quality control should include identity testing by NMR or FTIR, viscosity determination on each lot, and a moisture check after container opening. The certificate of analysis supplies lot-specific values, but no single-table release specification replaces the need for process qualification under the intended manufacturing equipment.

Because stannous octoate is used in the ring-opening polymerization of lactide and glycolide, tin content is a release parameter relevant to injectable products. The limit of ≤ 200 ppm should be interpreted against the elemental impurity control strategy of the finished dosage form under ICH Q3D. For parenteral products, the risk assessment must consider the maximum daily dose, the polymer content per unit dose, and the potential for tin accumulation from multiple injections. Residual monomers and degradation products such as lactide, glycolide, lactic acid, and glycolic acid are also part of the stability-indicating profile. During hydrolytic degradation, the molecular weight distribution shifts toward lower values before mass loss becomes detectable; therefore gel permeation chromatography should be monitored in addition to pH, water uptake, and mechanical integrity of the implant or microsphere. Published data for this specific grade under all storage temperatures and injection formulations are limited; lot-specific stability studies are required.

For long-acting injectable dosage forms, RG 503 H is selected when a 50:50 PLGA with free carboxyl terminal chemistry is required to achieve a shorter depot lifetime than ester-capped equivalents. Microspheres and implants formulated with this grade are intended for intramuscular or subcutaneous administration; the polymer matrix controls drug availability by hydrolysis rather than enzymatic cleavage. In peptide and protein delivery, the acid chain ends may interact electrostatically with basic amino acid residues, and formulation screening should evaluate adsorption, aggregation, and acylation under forced-degradation conditions before selecting the grade. In vitro release testing can be performed using USP <711> Apparatus 4 flow-through cells with phosphate-buffered saline at pH 7.4 and 37 °C; sampling intervals are typically adjusted to the expected 2–4 week release period for 50:50 PLGA microparticles. In situ forming implants based on N-methyl-2-pyrrolidone solutions of RG 503 H gel upon injection, and the release profile depends on solvent exchange rate, polymer concentration, and tissue uptake of the solvent. Nanoparticles produced by nanoprecipitation or high-pressure homogenization require tighter control of organic phase viscosity, and residual solvent should be tested by headspace GC according to USP <467> or equivalent. For sterile products, terminal gamma irradiation or aseptic processing may be used; irradiation doses above 25 kGy can reduce molecular weight and alter release, so qualification of the sterilized final product is mandatory. Published data for this specific grade under high-dose gamma irradiation are limited.

When a Production Line Transitions from RG 502 H to RG 503 H

RG 502 H, RG 503 H, RG 504 H, and RG 505 H share acid-terminated 50:50 PLGA chemistry but differ in molecular weight and solution viscosity. Manufacturer specifications bracket the series at approximately 0.16–0.24 dL/g for RG 502 H, 0.32–0.44 dL/g for RG 503 H, 0.45–0.60 dL/g for RG 504 H, and 0.61–0.75 dL/g for RG 505 H. A switch from RG 502 H to RG 503 H raises the molecular weight of the matrix and usually extends the degradation and release interval, but the magnitude of the extension depends on particle size, drug loading, and the in vitro test configuration. On a twin-screw extruder used for implant manufacture, a higher-viscosity grade increases melt pressure and torque at a fixed screw speed; the barrel temperature set points, feed rate, and die geometry should be re-qualified. In solvent-based microsphere lines, the higher organic-phase viscosity shifts the droplet breakup point in rotor-stator homogenization, potentially increasing the median particle size if tip speed and residence time are not adjusted. The same change can raise encapsulation efficiency for hydrophobic drugs because the more viscous organic phase delays drug partitioning to the continuous phase. These effects are equipment-dependent and cannot be predicted solely from the 0.1% w/v inherent viscosity value. A documented grade-change study should compare particle size distribution, residual solvent, encapsulation efficiency, and USP <711> release profiles across at least three lots of each grade. Line clearance and drying validation remain mandatory because residual moisture from the previous run can induce hydrolysis during the start-up phase. Published data for this specific transition on production-scale equipment is limited.